Repository logo
 

Chemerin signalling in adipose tissue and intestinal homeostasis

dc.contributor.authorDranse, Helen
dc.contributor.copyright-releaseYesen_US
dc.contributor.degreeDoctor of Philosophyen_US
dc.contributor.departmentDepartment of Pharmacologyen_US
dc.contributor.ethics-approvalReceiveden_US
dc.contributor.external-examinerDr. Benjamin Tsangen_US
dc.contributor.graduate-coordinatorDr. Kishore Pasumarthien_US
dc.contributor.manuscriptsYesen_US
dc.contributor.thesis-readerDr. Johan van Limbergenen_US
dc.contributor.thesis-readerDr. James Fawcetten_US
dc.contributor.thesis-supervisorDr. Christopher Sinalen_US
dc.date.accessioned2016-02-10T17:40:15Z
dc.date.available2016-02-10T17:40:15Z
dc.date.defence2016-01-28
dc.date.issued2016-02-10T17:40:15Z
dc.description.abstractChemerin is an adipokine and potent chemoattractant for cells expressing chemokine-like receptor 1 (CMKLR1) which plays important roles in metabolism and immunity. Chemerin is secreted as inactive prochemerin and undergoes extracellular processing to generate a variety of isoforms that range in bioactivity. Clinical studies have demonstrated that chemerin levels are positively associated with obesity and inflammatory disorders. However, the role of chemerin signalling in adipose tissue, and how elevated chemerin levels affect inflammatory disease progression, are poorly understood. In this thesis, I describe the development of techniques to modulate levels of chemerin signalling. I then investigate the role of chemerin signalling in three physiological contexts: mature adipocytes, pathogenesis of colitis, and intestinal microbiome composition. Using a microarray-based approach, I identified matrix metalloproteinase (MMP)3 and several chemokines as novel targets of chemerin signalling in adipocytes. Decreased chemerin levels resulted in increased MMP activity and macrophage migration towards adipocyte-conditioned media, via an NFkB-dependent mechanism. This suggests that elevated chemerin levels with obesity influence adipose tissue remodelling. Importantly, these effects were mediated through a unique adipocyte-processed chemerin isoform. I next demonstrated that local expression, secretion, and processing of chemerin were positively associated with colonic inflammation in a colitis model. CMKLR1 knockout (KO) mice developed signs of clinical illness more slowly than wildtype, but ultimately developed similar levels of inflammation. Intraperitoneal injection of bioactive chemerin had no effect on colitis severity, suggesting that local chemerin levels have a greater impact on the pathogenesis of colitis. Finally, I investigated differences in intestinal microbiome composition between wildtype, chemerin KO, and CMKLR1 KO mice. Significant differences in Akkermansia and Prevotella abundance were observed in the absence of CMKLR1. These bacterial populations are known to correlate with adiposity and glucose homeostasis, indicating that chemerin signalling might influence metabolic processes through modulation of microbiome composition. Considered altogether, this work demonstrates that local chemerin signalling and processing plays autocrine/paracrine roles in adipose tissue and intestinal homeostasis. Additionally, chemerin represents a novel biomarker in colon inflammation. Modulation of local, context-specific chemerin signalling therefore represents a potential therapeutic target for the treatment of metabolic and inflammatory processes.en_US
dc.identifier.urihttp://hdl.handle.net/10222/70764
dc.language.isoenen_US
dc.subjectchemerinen_US
dc.subjectadipokineen_US
dc.subjectadipocyteen_US
dc.subjectinflammatory bowel diseaseen_US
dc.subjectmicrobiomeen_US
dc.titleChemerin signalling in adipose tissue and intestinal homeostasisen_US
dc.typeThesis

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Dranse-Helen-PhD-PHAC-January-2016.pdf
Size:
18.72 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: